A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
This page links out to registry/source records, the global trial tracker, the updates feed, and the matching wiki dossier.
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Not listed | Lead sponsor: University of California, Irvine | Conditions: Opioid Use Disorder (OUD)
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Withdrawn | Official title: Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms | Sponsor: Johns Hopkins University | Conditions: PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries | Interventions: Hormone Replacement Therapy (HRT); Magnetic Resonance Therapy (MeRT); ibogaine with magnesium treatment; 5-MeO-DMT | Study type: Interventional
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: International Center for Ethnobotanical Education, Research, and Service | Official title: Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone | Condition: Opioid Dependence | Intervention: Ibogaine Hydrochloride | Study type: Interventional
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Active, not recruiting | Official title: A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Sequelae of Repeated Blast Exposure | Sponsor: Stanford University | Conditions: Blast or Combat Exposure; Head Injury Trauma | Intervention: ibogaine with magnesium treatment | Study type: Observational
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Completed | Official title: Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | Sponsor: University of Sao Paulo | Condition: Alcoholism | Intervention: Ibogaine Hydrochloride | Study type: Interventional
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: atai Therapeutics, Inc. | Conditions: Opiate Withdrawal Syndrome
Last checked: 2026-05-17 07:00 UTC. FDA EO/CNPV page still names voucher indications — psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD — but does not name the psilocybin/MDD company. Claim boundary: regulatory-process/indication list only; not approval, not safety/effectiveness finding, not label/access/reimbursement, and not primary confirmation of the psilocybin/MDD sponsor.
FDA page excerpt in direct scrape: national priority vouchers to companies studying psilocybin for TRD, psilocybin for MDD, methylone for PTSD; no company named for psilocybin/MDD in checked text.
PubMed PMID 42129626 reports that single-dose ibogaine in adult mice restored juvenile-like experience-dependent plasticity in visual cortex after monocular deprivation and was accompanied by changes in perineuronal nets, parvalbumin staining, and inhibitory synaptic markers.
Last checked 2026-05-15 UTC. Claim boundary: preclinical mouse neuroplasticity study only; not human addiction, depression, PTSD, Parkinson's, clinical efficacy, broad safety, approval, label, reimbursement, or access evidence.